Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OSU-2131 + QS-21
- Development stage
- Phase 1
- Lead developer
- The Ohio State University Comprehensive Cancer Center - James Cancer Hospital
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
OSU-2131 is an investigational peptide vaccine complex consisting of recombinant human heat shock protein 70 (rh-Hsc70) and a synthetic peptide (RAKFKQLL) derived from the Epstein-Barr virus (EBV) BZLF1 protein. Developed by the Ohio State University Comprehensive Cancer Center, it is administered with the saponin-based adjuvant QS-21 (Stimulon) to enhance immunogenicity. The vaccine is designed to prevent EBV infection and associated malignancies, such as post-transplant lymphoproliferative disorder (PTLD), particularly in high-risk populations like solid organ transplant candidates who are undergoing immunosuppression. It works by priming the immune system to recognize and eliminate EBV-infected cells by targeting the BZLF1 early lytic protein, which is essential for the virus's transition from latency to replication.
- Other names
- rh-Hsc70-BZLF1 peptide complexrh-Hsc-70-BZLF1 peptide complexrh-Hsc 70-BZLF1 peptide complexBZLF1 peptide vaccineBZLF-1 peptide vaccineBZLF 1 peptide vaccinerh-Hsc70-BZLF1rh-Hsc-70-BZLF1rh-Hsc 70-BZLF1
02
Targets
CholesterolHSPA8 (Heat shock cognate 71 kDa protein)MHC-presented Epstein-Barr virus BZLF1 epitopeBZLF1 (Epstein-Barr virus replication and transcription activator)
Beyond the preview
Go deeper on OSU-2131 + QS-21.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OSU-2131 + QS-21.